Stay updated with breaking news from Cyte corporation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock. Several other brokerages have also issued reports on OCX. Stephens reiterated an “equal weight” rating and issued a $4.00 price target on shares […] ....
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. Several other brokerages have also recently weighed in on OCX. Needham & Company LLC reiterated a buy rating and issued a $4.25 price objective on shares of OncoCyte […] ....
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the stock. A number of other research firms have also recently commented on OCX. Benchmark restated a speculative buy rating and issued a $5.00 price objective on shares of OncoCyte […] ....
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.